(Q34172972)

31 July 2017

1 reference

title

What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? (English)

1 reference

31 July 2017

V Ozdemir

1

1 reference

31 July 2017

N H Shear

series ordinal

2

1 reference

31 July 2017

W Kalow

series ordinal

3

1 reference

31 July 2017

1 January 2001

1 reference

31 July 2017

1 reference

31 July 2017

24

1 reference

31 July 2017

75-85

1 reference

31 July 2017

2

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200124020-00001

31 July 2017

0 references

cites work

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

1 reference

12 December 2020

Genomic sciences and the medicine of tomorrow

1 reference

12 December 2020

Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment

1 reference

12 December 2020

Methylation pharmacogenetics: thiopurine methyltransferase as a model system

1 reference

12 December 2020

Drug distribution. The forgotten relative in clinical pharmacokinetics

1 reference

12 December 2020

Functional genomics: technological challenges and opportunities

1 reference

12 December 2020

Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles

1 reference

12 December 2020

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

1 reference

12 December 2020

The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods

1 reference

12 December 2020

Pharmacogenetics in biological perspective.

1 reference

12 December 2020

CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations

1 reference

12 December 2020

Pharmacogenetic research: a revolutionary science

1 reference

12 December 2020

If I had a gene test, what would I have and who would I tell?

1 reference

12 December 2020

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

1 reference

12 December 2020

Pharmacogenetics of schizophrenia

1 reference

12 December 2020

Drug-Metabolizing Enzymes and Therapeutic Drug Monitoring in Psychiatry

1 reference

12 December 2020

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

1 reference

12 December 2020

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

1 reference

12 December 2020

Avoiding casualties in the genetic revolution: the urgent need to educate physicians about genetics

1 reference

12 December 2020

Genetic dissection of complex traits

1 reference

12 December 2020

Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology

1 reference

12 December 2020

Enzyme induction in the cytochrome P-450 system

1 reference

12 December 2020

Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case

1 reference

12 December 2020

In vitro metabolic interaction studies: experience of the Food and Drug Administration

1 reference

12 December 2020

Drug transporters in psychopharmacology--are they important?

1 reference

12 December 2020

The science of pharmacological variability: an essay

1 reference

12 December 2020

Drug reactions enzymes, and biochemical genetics

1 reference

12 December 2020

Genetic variation of CNS receptors--a new perspective for pharmacogenetics.

1 reference

12 December 2020

Pharmacogenomics: translating functional genomics into rational therapeutics

1 reference

12 December 2020

Detection of populations at risk and problem drugs during drug development and in pharmacotherapy.

1 reference

12 December 2020

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

1 reference

12 December 2020

Biotransformation enzyme polymorphism and pesticide susceptibility.

1 reference

12 December 2020

Genomics and drugs: finding the optimal drug for the right patient

1 reference

12 December 2020

Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)

1 reference

12 December 2020

The advent of the "unpatients'.

1 reference

12 December 2020

Genetic variation as a guide to drug development

1 reference

12 December 2020

Antidepressants and drug-metabolizing enzymes--expert group report

1 reference

12 December 2020

The intellectual health of clinical drug evaluation

1 reference

12 December 2020

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

1 reference

12 December 2020

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

1 reference

12 December 2020

Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia.

1 reference

12 December 2020

Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

The emerging field of ecogenetics

1 reference

12 December 2020

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

1 reference

12 December 2020

Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption

1 reference

12 December 2020

Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics.

1 reference

12 December 2020

Populations and genetic polymorphisms

1 reference

12 December 2020

Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population.

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

1 reference

12 December 2020

Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis

1 reference

12 December 2020

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

1 reference

12 December 2020

Ethnicity and psychopharmacology. Bridging the gap

1 reference

12 December 2020

Cytochrome P450-mediated drug interactions.

1 reference

12 December 2020

St John's Wort: effect on CYP3A4 activity

1 reference

12 December 2020

Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia

1 reference

12 December 2020

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

12 December 2020

Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability

1 reference

12 December 2020

DNA microarrays in drug discovery and development

1 reference

12 December 2020

Applications of DNA chips for genomic analysis

1 reference

12 December 2020

Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking

1 reference

12 December 2020

The millennium of mind, brain, and behavior

1 reference

12 December 2020

Pharmacogenomics and the changing face of clinical pharmacology

1 reference

12 December 2020

Short- and long-term projections about the use of drug metabolism in drug discovery and development.

1 reference

12 December 2020

Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans

1 reference

12 December 2020

The pharmacogenetics of codeine hypoalgesia.

1 reference

12 December 2020

Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research

1 reference

12 December 2020

Technologies for detecting genetic polymorphisms in pharmacogenomics

1 reference

12 December 2020

Indinavir concentrations and St John's wort.

1 reference

12 December 2020

The past, present and future of clinical pharmacology

1 reference

12 December 2020

Learning versus confirming in clinical drug development

1 reference

12 December 2020

Criteria for the choice and definition of healthy volunteers and or patients for phase I and phase II studies in drug development. Commentary on an action for cooperative research

1 reference

12 December 2020

10.2165/00002018-200124020-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference